Brazil reported over 8,000 Oropouche cases in 2024, more than the previous 40 years combined, with the virus spreading from the Amazon basin into all five Brazilian regions. Cuba confirmed its first outbreak in May 2024. Imported cases reached Italy, Germany, Spain, and the United States by late 2024. PAHO declared an epidemiological alert in February 2024 that has not been lifted in 2026.
Two stillbirths and four cases of probable congenital infection in 2024 forced a rapid rethink of an arbovirus that had been considered self-limiting since the 1960s. This post complements Zika and pregnancy travel and the climate change and infectious disease overview, and sits inside the broader disease severity framework.
Key Takeaways
- Oropouche virus (OROV) is an orthobunyavirus transmitted primarily by the biting midge Culicoides paraensis.
- Brazil reported over 8,000 cases in 2024, up from typical annual averages under 200.
- First confirmed deaths and probable congenital infections were documented in 2024.
- Symptoms mimic dengue: fever, headache, retro-orbital pain, myalgia, photophobia.
- No vaccine, no specific antiviral, no licensed diagnostic outside reference labs.
- Range expansion is linked to deforestation, climate change, and increased Culicoides density.
What is Oropouche virus?
Oropouche virus is a segmented, negative-sense RNA virus in the Peribunyaviridae family. It was first isolated in 1955 from a Trinidadian forest worker. The natural sylvatic cycle involves sloths, non-human primates, and mosquitoes. Urban outbreaks are driven by midges biting infected humans and then spreading the virus person to vector to person.
The virus has three genome segments (S, M, and L) and reassorts readily. The 2024-2026 expansion involves a novel reassortant lineage with the M segment from a Peruvian strain combined with S and L segments from Amazonian ancestors. The reassortant appears to spread more efficiently in urban settings.
Oropouche is sometimes called sloth fever in older literature because three-toed sloths are the most consistent wild reservoir.
How does it spread?
The biting midge Culicoides paraensis is the primary urban vector. These midges are smaller than mosquitoes, breed in rotting banana stems and decaying vegetation, and bite at dawn and dusk. Standard mosquito control measures miss them, and standard window screens often have holes wider than a midge.
Culex quinquefasciatus, the common southern house mosquito, can also transmit OROV experimentally. Field evidence for mosquito-driven outbreaks is weaker but contributes to the geographic expansion.
Sexual transmission has been documented in at least one Italian case, and vertical transmission from mother to fetus is now strongly suspected in Brazilian congenital cases. Blood transfusion remains theoretical but plausible given high viremia in symptomatic patients.
What are the symptoms?
Symptoms appear 3 to 12 days after a midge bite. Sudden fever, severe headache, retro-orbital pain, myalgia, arthralgia, photophobia, and rash mark the acute phase. Most patients recover in 5 to 7 days, but roughly 60 percent relapse with milder symptoms 1 to 2 weeks later. Aseptic meningitis develops in around 4 percent of cases.
| Phase | Days | Features |
|---|---|---|
| Incubation | 3 to 12 | No symptoms |
| Acute | 1 to 7 | Fever, retro-orbital pain, myalgia, rash, photophobia |
| Convalescent | 7 to 14 | Improvement |
| Relapse | 14 to 28 | Recurring fever, headache (about 60 percent) |
| Neurological | rare | Aseptic meningitis, encephalitis, Guillain-Barré-like |
Clinical overlap with dengue, chikungunya, and Zika is near-total. Differentiation needs PCR, and most regional laboratories cannot yet distinguish OROV from related arboviruses without sending samples to Fiocruz or PAHO reference centers.
What is the congenital risk?
Brazilian authorities documented two stillbirths and four probable congenital infections in 2024 with microcephaly, brain calcifications, and corpus callosum abnormalities resembling congenital Zika syndrome. OROV RNA was detected in fetal tissue and amniotic fluid. The mechanism appears to be direct placental infection in the first or second trimester.
PAHO and WHO updated guidance in late 2024 advising pregnant travelers to avoid Oropouche outbreak areas. The advice mirrors but is more cautious than current Zika guidance because the absolute risk numbers are still uncertain.
If you are pregnant and live in an affected area, midge avoidance (long sleeves, DEET, fine mesh bed nets) is the only effective intervention. Standard travel mosquito advice underprotects against Culicoides.
Where is OROV now?
Brazil drives the case count. Amazonas, Rondônia, Pará, and Espírito Santo states bore most of the 2024 burden. The reassortant strain reached São Paulo and Rio Grande do Sul in early 2025. Bolivia, Peru, Colombia, and Cuba have confirmed local transmission.
Outside the Americas, all 2024-2025 cases were imported in travelers returning from Cuba or Brazil. Italy logged 5 cases. Germany 2. Spain 12. The US logged its first cases in Florida and New York in mid-2024.
Surveillance gaps make the true picture worse than the case count suggests. Underdiagnosis is severe because clinicians do not yet test for OROV in dengue-endemic regions. PAHO estimates true incidence is 10 to 20 times reported numbers.
How do you avoid Oropouche?
The vector is small, fast, and bites in twilight. Effective avoidance combines DEET 30 percent or picaridin 20 percent on skin, permethrin-treated clothing, fine-mesh (0.6 mm or finer) bed nets, and avoiding outdoor exposure at dawn and dusk in affected areas.
Standard mosquito screens with 1.2 mm mesh let Culicoides through. If you live or work in an outbreak zone, upgrading to fine mesh on windows is one of the few household interventions with real impact. Read the mosquito-borne disease prevention guide for broader insect-bite strategy.
Eliminating breeding sites is harder than for mosquitoes. Culicoides breed in moist organic debris, not standing water. Drying out compost piles, banana plant bases, and forest-edge vegetation reduces local populations.
FAQ
Is Oropouche the new Zika?
The parallel is real but incomplete. Like Zika in 2015-2016, Oropouche is an arbovirus expanding rapidly with possible congenital sequelae. Unlike Zika, the vector is a midge not a mosquito, the reassortant biology is different, and the absolute congenital risk numbers are still unknown. Caution is warranted; panic is not.
Can you test for Oropouche at a regular clinic?
Not in 2026. There is no licensed point-of-care or commercial diagnostic. Confirmation requires RT-PCR on serum, CSF, or urine at a reference laboratory (Fiocruz, PAHO centers, CDC, ECDC). Serology cross-reacts heavily with other orthobunyaviruses and is unreliable.
Is there a vaccine in development?
Yes, at least three candidates entered preclinical work in 2024-2025: an mRNA platform, an inactivated whole-virus candidate, and a viral vector approach. None have entered human trials as of mid-2026. A licensed vaccine is unlikely before 2028.
Should travelers cancel trips to Brazil?
CDC recommends pregnant travelers avoid affected areas. Other travelers should use rigorous midge and mosquito avoidance and watch for fever for 14 days after return. Most trips proceed safely with these precautions. Travel insurance with medical evacuation coverage is worth verifying.
How is Oropouche different from dengue?
Clinically the two are hard to tell apart in the first 72 hours. Dengue causes hemorrhagic complications and plasma leakage; Oropouche typically does not. Dengue has a licensed vaccine and a clear rapid test; Oropouche has neither. Both circulate in the same regions and may co-infect the same patient.